Detail of "199685-57-9"

Reference

Biologics in inflammatory bowel disease: how much progress have we made?

Biologics in inflammatory bowel disease: how much progress have we made?. Sandborn, W. J.Chemicals with cas numbers 199685-57-9 and 170277-31-3 also play role.; Faubion, W. A. (Mayo Clinic, Rochester, MN 55905, USA). Gut, 53(9), 1366-1373 (English) 2004 BMJ Publishing Group. CODEN: GUTTAK. ISSN: 0017-5749. DOCUMENT TYPE: Journal; General Review CA Section: 15 (Immunochemistry) Section cross-reference(s): 1 A review on the progress made to date in the treatment of inflammatory bowel diseases with biol. therapies. The main focus is on the tumor necrosis factor inhibitors infliximab, etanercept, adalimumab, CDP870, CDP571, and onercept, and on the selective adhesion mol. inhibitors natalizumab and MLN-02. Other potentially promising therapies targeted towards other mechanisms of action are also considered. .

Use and methods of use of etanercept and other TNF binding biologics to improve human cognitive function

Use and methods of use of etanercept and other TNF binding biologics to improve human cognitive function. Tobinick, Edward Lewis (USA ). U.S. Pat. Appl. Publ. US 2006009450 A1 12 Jan 2006,22 pp., Cont.-in-part of U.S. Provisional Ser. No. 585,735. (English). (United States of America). CODEN: USXXCO. APPLICATION: US 2004-16047 18 Dec 2004. PRIORITY: US 2004-2004/PV585735 6 Jul 2004. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 15, 63 The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function in three different broad categories of conditions. Cognitive impairment which is characteristic of certain neurol. disorders (for example Alzheimer's Disease, Idiopathic Dementia, and Traumatic Brain Injury). Cognitive impairment which accompanies certain systemic or localized non-neurol. conditions which are known or suspected to be assocd. with increased TNF (for example rheumatoid arthritis, psoriasis, and cancer cachexia); and 6. To enhance cognitive function in individuals in whom there is either no brain pathol. or in whom the existence of brain pathol. is either unknown or undefined, including a human without known disease. The pathol. conditions included in category 1 above include dementia or cognitive impairment suspected or established to be due to Alzheimer-type pathol., including Mild Cognitive Impairment, Possible Alzheimer's Disease, Probable Alzheimer's Disease, Alzheimer's Disease, and Senile Dementia/Alzheimer's type; Idiopathic Dementia or Dementia of unknown cause; Dementia with Lewy Bodies, also called Diffuse Lewy Body Disease; Picks Disease and other forms of frontotemporal dementia; cognitive impairment due to traumatic brain injury; AIDS (HIV) Dementia and Vascular Dementia. Cognitive impairment known to be due to infectious agents other than HIV or to brain tumors, either primary or metastatic, are not the subject of this patent. Category 2 conditions include those medical conditions known to be assocd. with increased TNF, and specifically include rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis, and, in addn., cancer cachexia or cancer metastatic to the spine. Also included Category 2 is chronic back pain. Category 3 includes normal individuals, without a known disease or disorder that has been established to be assocd. with elevated levels of TNF, who desire to achieve enhanced cognitive function. The methods of the present invention include not only the perispinal administration of etanercept (which itself can be accomplished in various ways, including transcutaneous interspinous injection, or catheter delivery into the epidural or interspinous space) but also other novel methods of localized administration, specifically including intranasal administration. For the purposes of this patent "perispinal" is to be considered as referring to "perispinal extrathecal"; therefore direct intrathecal administration is excluded from the methods discussed. Perispinal administration involves anatomically localized delivery performed so as to place the therapeutic mol. directly in the vicinity of the spine, and, for the purposes of this patent, administration which is outside of the intrathecal space (although subsequent movement of the therapeutic mol. into the intrathecal space does occur). Perispinal administration includes, but is not limited to, the following types of administration: parenteral; s.c.; i.m.; interspinous; epidural; or peridural, and specifically includes the use of interspinous injection carried through the skin in the midline of the neck or back, directly overlying the spine; or administration via an indwelling epidural catheter, or via an indwelling catheter which delivers etanercept to the interspinous space. Perispinal administration leads to enhanced delivery of etanercept to the brain in a therapeutically effective amt., via the vertebral venous system and/or the cerebrospinal fluid. Delivery of etanercept to the brain utilizing the methods of the present invention includes the use of the vertebral venous system to deliver etanercept to the brain via retrograde venous flow. In addn. to percutaneous injection into the interspinous space, etanercept may also be delivered to the interspinous or epidural space by implantable catheter, with the catheter reservoir placed remotely, such as in the abdominal area. Phys. maneuvers are used to enhance delivery of etanercept to the brain via this route. 199685-57-9 and 185243-69-0 are just another two chemicals used in this study. In addn. to etanercept there are two other non-monoclonal antibody TNF binding biologics of consideration in this patent: onercept (Serono) and pegylated sol. TNF receptor type 1 (Amgen). .